Exelixis | EXEL - Current Assets


Exelixis reported $1.25B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.22B 128.53M Jun/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Akebia Therapeutics USD 229.55M 13.93M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Bayer EUR 33.64B 1.66B Jun/2026
BioMarin Pharmaceutical USD 3.97B 633.45M Jun/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Cytokinetics USD 1.21B 369.02M Jun/2026
Eisai JPY 883.01B 121.38B Jun/2026
Eli Lilly USD 64.67B 9.84B Jun/2026
Exelixis USD 1.25B 42.18M Jun/2026
Genmab DKK 2.8B 228M Jun/2026
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
MacroGenics USD 321.69M 139.16M Jun/2026
Merck USD 36.68B 1.66B Jun/2026
Moderna USD 5.82B 45M Jun/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Novartis USD 27.35B 744M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Sanofi EUR 30.16B 789M Mar/2026
Takeda JPY 3.15T 59.77B Jun/2026
Ultragenyx Pharmaceutical USD 606M 51M Jun/2026
Xencor USD 523.21M 40.36M Jun/2026